NASDAQ:ALMS Alumis (ALMS) Stock Price, News & Analysis $11.96 +0.18 (+1.53%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$11.70▼$12.0550-Day Range$11.09▼$13.0052-Week Range$10.45▼$13.53Volume143,961 shsAverage Volume147,083 shsMarket Capitalization$557.68 millionP/E RatioN/ADividend YieldN/APrice Target$27.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrends Get Alumis alerts: Email Address Ad Weiss Ratings“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.Learn these 4 simple steps and protect your savings before it’s too late. About Alumis Stock (NASDAQ:ALMS)Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.Read More ALMS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALMS Stock News HeadlinesSeptember 6 at 8:07 AM | americanbankingnews.comAlumis (NASDAQ:ALMS) Shares Gap Up to $12.20September 3, 2024 | globenewswire.comAlumis to Participate in Upcoming September Investor ConferencesSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 27, 2024 | msn.comVisions Of Mana Review - A Pilgrimage To The PastAugust 19, 2024 | msn.comAutonomous mowers in school fields of the futureAugust 18, 2024 | msn.comIndore: Authorities’ Tall Claims Fall Flat, Beggary Still Alive In CityAugust 17, 2024 | msn.comMotorsport Reunion celebrates its 50th anniversary | Monterey Car WeekAugust 15, 2024 | msn.comAnambra clamps down on street beggars, arrests 16September 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 15, 2024 | msn.comAnambra arrests 16 child beggars in night raidAugust 14, 2024 | uk.finance.yahoo.comAlumis Inc. (ALMS)August 13, 2024 | msn.comAnambra Govt goes after syndicates using children for alms begging, arrest 30 kidsAugust 13, 2024 | globenewswire.comAlumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate AchievementsAugust 12, 2024 | msn.comALMs revived in H West ward after a yearAugust 2, 2024 | markets.businessinsider.comBuy Rating Affirmed for Alumis Inc. on Strong Prospects for TYK2 Inhibitor ESK-001July 31, 2024 | finanznachrichten.deAlumis Inc.: Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque PsoriasisJuly 30, 2024 | msn.comThai King’s 72nd birthday celebrated by embassies, consulates worldwideJuly 29, 2024 | globenewswire.comAlumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque PsoriasisSee More Headlines Receive ALMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alumis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today9/07/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALMS Previous SymbolNASDAQ:ALMS CUSIPN/A CIK1847367 WebN/A Phone(650) 231-6625FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$27.50 High Stock Price Target$36.00 Low Stock Price Target$13.00 Potential Upside/Downside+129.9%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares46,629,000Free FloatN/AMarket Cap$557.68 million OptionableN/A BetaN/A 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key CompetitorsBausch Health CompaniesNYSE:BHCVerona PharmaNASDAQ:VRNAGemini TherapeuticsNASDAQ:GMTXVera TherapeuticsNASDAQ:VERAIntellia TherapeuticsNASDAQ:NTLAView All CompetitorsInstitutional OwnershipMaven Securities LTDBought 25,000 shares on 8/29/2024Ownership: 0.054%Millennium Management LLCBought 253,820 shares on 8/15/2024Ownership: 0.544%Yu FanBought 789,618 shares on 8/14/2024Ownership: 1.693%Ally Bridge Group NY LLCBought 618,750 shares on 8/14/2024Ownership: 1.327%SR One Capital Management LPBought 1,959,896 shares on 8/13/2024Ownership: 4.203%View All Institutional Transactions ALMS Stock Analysis - Frequently Asked Questions How have ALMS shares performed this year? Alumis' stock was trading at $12.37 at the beginning of 2024. Since then, ALMS stock has decreased by 3.3% and is now trading at $11.96. View the best growth stocks for 2024 here. How were Alumis' earnings last quarter? Alumis Inc. (NASDAQ:ALMS) released its quarterly earnings data on Tuesday, August, 13th. The company reported ($23.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.57) by $21.53. When did Alumis IPO? Alumis (ALMS) raised $210 million in an initial public offering on Friday, June 28th 2024. The company issued 13,125,000 shares at $16.00 per share. When did the company's quiet period expire? Alumis' quiet period expired on Wednesday, August 7th. Alumis had issued 13,125,000 shares in its IPO on June 28th. The total size of the offering was $210,000,000 based on an initial share price of $16.00. During the company's quiet period, insiders and underwriters involved in the IPO were prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company. Who are Alumis' major shareholders? Top institutional shareholders of Alumis include SR One Capital Management LP (4.20%), Yu Fan (1.69%), Ally Bridge Group NY LLC (1.33%) and Towerview LLC (0.66%). How do I buy shares of Alumis? Shares of ALMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALMS) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alumis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alumis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.